Human immunodeficiency virus type 1 vectors with alphavirus envelope glycoproteins produced from stable packaging cells

Journal of Virology

Volumn 79, Issue 3, 2005, Pages 1765-1771

  Strang, Blair L ^a,e   Takeuchi, Yasuhiro ^a   Relander, Thomas ^b   Richter, Johan ^b   Bailey, Ranbir ^a   Sanders, David A ^c   Collins, Mary K L ^a   Ikeda, Yasuhiro ^a,d  

^a UNIVERSITY COLLEGE LONDON   (United Kingdom)

^b LUND UNIVERSITY   (Sweden)

^c PURDUE UNIVERSITY   (United States)

^d Mayo Clinic   (United States)

^e INSTITUTE OF VIROLOGY   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

CD34 ANTIGEN; VIRUS ENVELOPE PROTEIN; VIRUS GLYCOPROTEIN; GLYCOPROTEIN;

ALPHA VIRUS; ANIMAL CELL; ARTICLE; CELL CULTURE; CELL SPECIFICITY; DENDRITIC CELL; HEMATOPOIETIC STEM CELL; HUMAN; HUMAN CELL; HUMAN IMMUNODEFICIENCY VIRUS 1; MOUSE; NONHUMAN; PRIORITY JOURNAL; ROSS RIVER ALPHA VIRUS; VIRUS CELL INTERACTION; VIRUS ENVELOPE; ANIMAL; CELL LINE; EVALUATION; GENE VECTOR; GENETIC TRANSDUCTION; GENETICS; METABOLISM; PHYSIOLOGY; SEMLIKI FOREST ALPHAVIRUS; T LYMPHOCYTE; VIROLOGY; VIRUS ASSEMBLY;

ALPHAVIRUS; ANIMALS; CELL LINE; CELLS, CULTURED; DENDRITIC CELLS; GENETIC VECTORS; GLYCOPROTEINS; HEMATOPOIETIC STEM CELLS; HIV-1; HUMANS; MICE; ROSS RIVER VIRUS; SEMLIKI FOREST VIRUS; T-LYMPHOCYTES; TRANSDUCTION, GENETIC; VIRAL ENVELOPE PROTEINS; VIRUS ASSEMBLY;

EID: 13744261478     PISSN: 0022538X     EISSN: None     Source Type: Journal    
DOI: 10.1128/JVI.79.3.1765-1771.2005     Document Type: Article

References (34)

1. Arai, T., K. Matsumoto, K. Saitoh, M. Ui, T. Ito, M. Murakami, Y. Kanegae, I. Saito, F.-L. Cosset, Y. Takeuchi, and H. Iba. 1998. A new system for stringent, high-titer vesicular stomatitis virus G protein-pseudotyped retrovirus vector induction by introduction of Cre recombinase into stable prepackaging cell lines. J. Virol. 72:1115-1121.
2. Beyer, W. R., M. Westphal, W. Ostertag, and D. von Laer. 2002. Oncoretrovirus and lentivirus vectors pseudotyped with lymphocytic choriomeningitis virus glycoprotein: generation, concentration, and broad host range. J. Virol. 76:1488-1495.
3. Blaese, R. M., K. W. Culver, A. D. Miller, C. S. Carter, T. Fleisher, M. Clerici, G. Shearer, L. Chang, Y. Chiang, P. Tolstoshev, J. J. Greenblatt, S. A. Rosenberg, H. Klein, M. Berger, C. A. Mullen, W. J. Ramsey, L. Muul, R. A. Morgan, and W. F. Andersen. 1995. T-lymphocyte directed gene therapy for ADA-SCID: initial trial results after 4 years. Science 270:480.
4. Bordignon, C., L. D. Notarangelo, N. Nobili, G. Ferrari, G. Casorati, P. Panina, E. Mazzolari, D. Maggioni, C. Rossi, P. Servida, A. G. Ugazio, and F. Mavilio. 1995. Gene therapy in peripheral blood lymphocytes and bone marrow for ADA-immunodeficient patients. Science 270:470-475.
5. Burns, J. C., T. Friedmann, W. Driever, M. Burrascano, and J. K. Yee. 1993. Vesicular stomatitis virus G glycoprotein pseudotyped retroviral vectors: concentration to very high titer and efficient gene transfer into mammalian and nonmammalian cells. Proc. Natl. Acad. Sci. USA 90:8033-8037.
6. Cavazzana-Calvo, M., S. Hacien-Bey, G. de Saint Basile, F. Gross, E. Yvon, P. Nusbaum, F. Selz, C. Hue, S. Certain, J. L. Casanova, P. Bousso, F. L. Deist, and A. Fischer. 2000. Gene therapy of human severe combined immunodeficiency (SCID)-X1 disease. Science 288:669-672.
7. Demaison, C., K. Parsley, G. Brouns, M. Scherr, K. Battmer, C. Kinnon, M. Grez, and A. J. Thrasher. 2002. High-level transduction and gene expression in hematopoietic repopulating cells using a human imunodeficiency [sic] virus type 1-based lentiviral vector containing an internal spleen focus forming virus promoter. Hum. Gene Ther. 13:803-813.
8. DePolo, N. J., C. E. Harkleroad, M. Bodner, A. T. Watt, C. G. Anderson, J. S. Greengard, K. K. Murthy, T. W. Dubensky, Jr., and D. J. Jolly. 1999. The resistance of retroviral vectors produced from human cells to serum inactivation in vivo and in vitro is primate species dependent. J. Virol. 73:6708-6714.
9. DePolo, N. J., J. D. Reed, P. L. Sheridan, K. Townsend, S. L. Sauter, D. J. Jolly, and T. W. Dubensky, Jr. 2000. VSV-G pseudotyped lentiviral vector particles produced in human cells are inactivated by human serum. Mol. Ther. 2:218-222.
10. Esslinger, C., P. Romero, and H. R. MacDonald. 2002. Efficient transduction of dendritic cells and induction of a T-cell response by third-generation lentivectors. Hum. Gene Ther. 13:1
11. Firat, H., V. Zennou, F. Garcia-Pons, F. Ginhoux, M. Cochet, O. Danos, F. Lemonnier, P. Langlade-Demoyen, and P. Charneau. 2002. Use of a lentiviral flap vector for induction of CTL immunity against melanoma. Perspectives for immunotherapy. J. Gene Med. 4:38-45.
12. Griffin, D. E. 2001. Alphaviruses, p. 917-963. In D. M. Knipe, P. M. Howley, D. E. Griffin, et al. (ed.), Fields virology, 4th ed. Lippincott Williams & Wilkins, Philadelphia, Pa.
13. Ikeda, Y., Y. Takeuchi, F. Martin, F. L. Cosset, K. Mitrophanous, and M. Collins. 2003. Continuous high-titer HIV-1 vector production. Nat. Biotechnol. 21:569-572.
14. Kahl, C. A., J. Marsh, J. Fyffe, D. A. Sanders, and K. Cornetta. 2004. Human immunodeficiency virus type 1-derived lentivirus vectors pseudotyped with envelope glycoproteins derived from Ross River virus and Semliki Forest virus. J. Virol. 78:1421-1430.
15. Rang, Y., C. S. Stein, J. A. Heth, P. L. Sinn, A. K. Penisten, P. D. Staber, K. L. Ratliff, H. Shen, C. K. Barker, I. Martins, C. M. Sharkey, D. A. Sanders, P. B. McCray, Jr., and B. L. Davidson. 2002. In vivo gene transfer using a nonprimate lentiviral vector pseudotyped with Ross River Virus glycoproteins. J. Virol. 76:9378-9388.
16. Lam, J. S., M. E. Reeves, R. Cowherd, S. A. Rosenberg, and P. Hwu. 1996. Improved gene transfer into human lymphocytes using retroviruses with the gibbon ape leukemia virus envelope. Hum. Gene Ther. 7:1415-1422.
17. Linn, M. L., J. G. Aaskov, and A. Suhrbier. 1996. Antibody-dependent enhancement and persistence in macrophages of an arbovirus associated with arthritis. J. Gen. Virol. 77:407-411.
18. Loser, P., G. S. Jennings, M. Strauss, and V. Sandig. 1998. Reactivation of the previously silenced cytomegalovirus major immediate-early promoter in the mouse liver: involvement of NFκB. J. Virol. 72:180-190.
19. Mastromarino, P., C. Conti, P. Goldoni, B. Hauttecoeur, and N. Orsi. 1987. Characterization of membrane components of the erythrocyte involved in vesicular stomatitis virus attachment and fusion at acidic pH. J. Gen. Virol. 68:2359-2369.
20. Metharom, P., K. A. O. Ellem, C. Schmidt, and M. Q. Wei. 2001. Lentiviral vector-mediated tyrosinase-related protein 2 gene transfer to dendritic cells for the therapy of melanoma. Hum. Gene Ther. 10:2203-2213.
21. Morizono, K., G. Bristol, Y. M. Xie, S. K. Rung, and I. S. Chen. 2001. Antibody-directed targeting of retroviral vectors via cell surface antigens. J. Virol. 75:8016-8020.
22. Murphy, J. C., W. Fischle, E. Verdin, and J. H. Sinclair. 2002. Control of cytomegalovirus lytic gene expression by histone acetylation. EMBO J. 21: 1112-1120.
23. Naldini, L., U. Blomer, P. Gallay, D. Ory, R. Mulligan, F. H. Gage, I. M. Verma, and D. Trono. 1996. In vivo gene delivery and stable transduction of nondividing cells by a lentiviral vector. Science 272:263-267.
24. Overbaugh, J., A. D. Miller, and M. V. Eiden. 2001. Receptors and entry cofactors for retroviruses include single and multiple transmembrane-spanning proteins as well as newly described glycophosphatidylinositol-anchored and secreted proteins. Microbiol. Mol. Biol. Rev. 65:371-389.
25. Palmowski, M. J., L. Lopes, Y. Ikeda, M. Salio, V. Cerundolo, and M. K. Collins. 2004. Intravenous injection of a lentiviral vector encoding N.Y.-ESO-1 induces an effective CTL response. J. Immunol. 172:1582-1587.
26. + cells increases gene transfer mediated by GALV pseudotyped vectors. Mol. Ther. 6:400-406.
27. Sallusto, F., and A. Lanzavecchia. 1994. Efficient presentation of soluble antigen by cultured human dendritic cells is maintained by granulocyte/macrophage colony-stimulating factor plus interleukin 4 and downregulated by tumor necrosis factor alpha. J. Exp. Med. 179:1109-1118.
28. Schlegel, R., T. S. Tralka, M. C. Willingham, and I. Pastan. 1983. Inhibition of VSV binding and infectivity by phosphatidylserine: is phosphatidylserine a VSV-binding site? Cell 32:639-646.
29. Sharkey, C. M., C. L. North, R. J. Kuhn, and D. A. Sanders. 2001. Ross River virus glycoprotein-pseudotyped retroviruses and stable cell lines for their production. J. Virol. 75:2653-2659.
30. Song, W., H. L. Kong, H. Carpenter, H. Torii, R. Granstein, S. Rafti, M. A. Moore, and R. G. Crystal. 1997. Dendritic cells genetically modified with an adenovirus vector encoding the cDNA for a model antigen induce protective and therapeutic antitumor immunity. J. Exp. Med. 186:1247-1256.
31. Strang, B. L., Y. Ikeda, F. L. Cosset, M. K. Collins, and Y, Takeuchi. 2004. Characterization of HIV-1 vectors with gammaretrovirus envelope glycoproteins produced from stable packaging cells. Gene Ther. 11:591-598.
32. Strauss, J. H., and E. G. Strauss. 1994. The alphaviruses: gene expression, replication, and evolution. Microbiol. Rev. 58:491-562.
33. Zufferey, R., T. Dull, R. J. Mandel, A. Bukovsky, D. Quiroz, L. Naldini, and D. Trono. 1998. Self-inactivating lentivirus vector for safe and efficient in vivo gene delivery. J. Virol. 72:9873-9880.
34. Zufferey, R., D. Nagy, R. J. Mandel, L. Naldini, and D. Trono. 1997. Multiply attenuated lentiviral vector achieves efficient gene delivery in vivo. Nat. Biotechnol. 15:871-875.